Development↦Quality and Risk↦Quality Control↦Non-Compliance
What is it? Why is it important?
Non-compliance addresses the non-adherence to given instruction(s).
- The Ethics Committee (EC), and if applicable Swissmedic, approved study protocol
- Applicable regulatory requirements (e.g. Swiss Law, FOPH, international)
- Applicable guidelines (ICH GCP, ISO 14155, Biobanking)
- Study quality processes / documents (e.g. SOPs. WIs)
- Ethical principles
Protocol non-compliance may threaten the Critical-to-Quality factors of the study, such as participant safety and rights, data quality, regulatory compliance, and the scientific validity of the study.
Protocol non-compliance are classified either as a:
- Deviation: Less serious, accidental or unintentional non-compliance that does not significantly affect the study (e.g. minor timing deviation, missing signatures on the study delegation-log)
- Violation: More serious non-compliance that may lead to the exclusion of participants from data analysis, the inability to reach study outcome / endpoint, and/or discontinuation of the study (e.g. enrolment of non-eligible participants, use of expired investigational product (IMP / IMD), deviation from correct consent procedures)
What do I need to do?
As a SP-INV,
- Document all protocol deviations, including reasons for the deviation in a Note-to-File or a deviation log. Date and sign documents and file documents in the study TMF/ISF
- Assess non-compliance and its potential impact on the study (e.g. study timeline, quality-process adaptations (e.g. SOP, WI), study analysis and reporting, protocol amendment, resources, budget)
- Participants non-compliant may significantly jeopardise data quality and study outcome (e.g. unreliable medication intake). Plan procedures that support participant compliance, and plan measure to assess participant compliance during study conduct
- In the event of persistent non-compliance at a particular study site, decide to close the site and report non-compliance to the EC, and if applicable Swissmedic
Define procedures on how to handle non-compliance such as to:
- Perform a root-cause analysis of the deviation
- Define appropriate Corrective and Preventative Actions (CAPA).
- Train study staff on defined risk control-measures
- Document CAPAs and plan risk reviews
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R3) – see in particular guidelines
- Glossary Definition: Compliance
- 3.12 Noncompliance
ICH E8(R1) – see in particular
- 3.2 Critical to Quality Factors
ISO 9001:2015 (access liable to costs) – see in particular section
- Quality Management Systems